CRISPR Therapeutics AG (NASDAQ:CRSP) Position Increased by Westwood Holdings Group Inc.

Westwood Holdings Group Inc. increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 151.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,375 shares of the company’s stock after acquiring an additional 22,516 shares during the period. Westwood Holdings Group Inc.’s holdings in CRISPR Therapeutics were worth $2,019,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of CRSP. Principal Securities Inc. purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $41,000. Vanguard Personalized Indexing Management LLC bought a new position in CRISPR Therapeutics during the fourth quarter valued at about $265,000. Beacon Pointe Advisors LLC bought a new position in CRISPR Therapeutics during the fourth quarter valued at about $236,000. Brown Advisory Inc. bought a new position in CRISPR Therapeutics during the fourth quarter valued at about $235,000. Finally, Norges Bank bought a new position in CRISPR Therapeutics during the fourth quarter valued at about $38,661,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

Shares of CRSP opened at $48.18 on Monday. The business’s 50 day simple moving average is $50.45 and its 200-day simple moving average is $56.83. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. The company has a market capitalization of $4.09 billion, a P/E ratio of -17.71 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter last year, the company posted ($0.98) earnings per share. The business’s quarterly revenue was down 99.3% on a year-over-year basis. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Barclays cut their target price on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 6th. Chardan Capital dropped their price objective on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Truist Financial dropped their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Piper Sandler reiterated an “overweight” rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, June 17th. Finally, Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average price target of $75.63.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.